Merck to end US Victrelis distribution this year
Merck's Victrelis patients will have to find a new medication. The Wall Street Journal reports that the company informed the FDA that this is the last year it will sell the hepatitis C medication in the US. Merck will continue to sell Victrelis abroad.
Entrants from Gilead and AbbVie have upended the category of late, and the Journal notes that doctors had planned to use these new drugs long before they were competitors for protease inhibitors like Victrelis or Vertex's since-discontinued Incivek.
The Journal notes that Merck, unlike Vertex, will continue to fight it out in the hepatitis C space, albeit with a new oral it plans to file with the FDA later this year.